Rapid Finance Helps Community Financial Institutions Scale SMB Lending and Boost Non-Interest Income With Its Integrated LOS and Funding Network
With increasing competition from larger banks, community financial institutions need ways to streamline their SMB lending and retain their small business customers. Rapid Finance's LOS not only improves loan origination and underwriting, but now also gives FIs one-click access to an extensive funding network to expand non-interest income opportunities for loan applications that fall outside of their existing loan requirements.
Rapid Finance's Funding Network is a vast network of trusted lenders who are skilled at client service and small business growth. Now, with a single click in Decisioneer, community can refer loan applications to this network. When funded, the bank earns non-interest income, transforming declines into revenue opportunities while empowering their small business customers.
With 20 years of experience in small business lending, Rapid Finance is a trusted partner for financial institutions looking to scale their lending programs. By combining its LOS, Decisioneer, and the Funding Network, FIs can:
- Compete more effectively – Offer SMB borrowers a streamlined, digital lending experience and opportunities when compared to competition.
- Automate and accelerate SMB lending – Simplify application intake, streamline decisioning and approvals with integrated fraud prevention, KYC, KYB and credit scoring.
- Enhance borrower experience – A fully digital, white-labeled solution that simplifies document collection, verification and storage loan processing.
- Reduce costs and improve efficiency – Automate workflows, minimize manual processes and instead strengthen relationships with your business customers by adapting to their evolving needs
- Expand revenue opportunities – Seamlessly refer applicants outside their credit criteria to the funding network with one click and boost their non-interest income.
'With Decisioneer and the integrated Rapid Finance Funding Network, we are empowering community financial institutions to bring capital to small businesses more efficiently while unlocking new revenue opportunities,' said Will Tumulty, CEO of Rapid Finance. 'For 20 years, we've been committed to helping businesses access the capital they need and this solution further strengthens that mission, giving community financial institutions the tools to better compete with larger lenders while serving their business customers more effectively. With Rapid Finance's LOS and Funding Network, FIs can scale SMB lending, drive revenue and better serve their business customers – ensuring they stay competitive in today's evolving financial landscape.'
ICBA LIVE attendees can stop by the Rapid Finance booth to learn more about the Funding Network and Decisioneer.
About Rapid Finance
Since 2005, Rapid Finance has been supporting the growth and success of small businesses across the U.S. Powered by a thoughtful combination of technology, speed and deep industry expertise, Rapid Finance provides modular, flexible and scalable financing solutions to small businesses, as well as Lending-as-a-Service solutions customized to meet enterprise clients' needs. Learn more at www.rapidfinance.com.
CONTACT: MEDIA CONTACT:
Augusta Bauknight
For Rapid Finance
678-781-7214
[email protected] Arango
For Rapid Finance
678-781-7233
SOURCE: Rapid Finance
Copyright Business Wire 2025.
PUB: 03/11/2025 07:01 AM/DISC: 03/11/2025 07:01 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 hours ago
- Yahoo
Pandora Revenues Climb 8 Percent in Q2
Despite tough macro headwinds, Pandora posted 8 percent revenue growth in the second quarter, with like-for-like sales up 3 percent and an additional 5 percent boost from network expansion. During the quarter, organic sales reached 7.07 billion Danish kronor, or $990 million. More from WWD Pamela Anderson Channels Vintage Allure in Thom Browne at 'The Naked Gun' Premiere With Liam Neeson Pamela Anderson Channels Timeless Elegance in Rodarte Dress for 'The Naked Gun' London Premiere Pandora, Amazon Teamed Up To Take Down Global Counterfeiting Ring Operating profit reached 1.29 billion Danish kronor, or $181 million, with strong EBIT margins of around 24 percent due to pricing and cost efficiencies, said the company in its interim results published on Friday. Pandora maintained its goal of 'around 25 percent' in terms of EBIT, or earnings before interest and taxes, for 2026 — 24 percent if accounting for tariff headwind. With manufacturing spread out through Thailand, China, Vietnam and India, the company has been working on its tariff mitigation measures, switching up its supply chain as well as shipping product directly to Canada and Latin America as opposed to through its U.S. distribution center. The Copenhagen-based jeweler highlighted growth in the U.S. market, which remained strong at 8 percent during the period. 'We started changing the strategy in the U.S. around 2020, and since then, the U.S. business has doubled, we now have a 2 percent market share, the largest player has 4 percent. If that's anything to go by, that would suggest that there should be quite some runway for growth,' said Alexander Lacik, president and chief executive officer of Pandora. 'One part of this comes with expanding the network. This is still a mass market proposition, so distribution or easy access to the brand physically is critically important,' Lacik added. Sales declined in the U.K., Italy and France, but this was offset by double-digit growth in Spain, Portugal, the Netherlands and Poland, bringing overall European market increase to 1 percent. 'We expect share price pressure near term, reflecting weaker June and July like-for-like growth, particularly in key European markets and with the Moments platform,' Citi wrote in a research note. With the closure of 12 concept stores during the period, sales in China dropped 15 percent. Pandora expects to close up to 100 stores in China, up from 'at least 50' previously. 'We have a more fundamental issue in China which we need to fix. The problem is that our brand wasn't properly introduced when we first entered the Chinese market in 2015. This means Chinese consumers do not know what we stand for,' the company shared in a statement regarding China issues. 'China is the biggest jewelry market in the world, and we remain fully committed to the business there,' the company said. Lacik also detailed Pandora's plan to transform from a 'wristwear player' into a jewelry brand with expanded categories rooted in accessible luxury. Initiatives include the launch of its entry price point Minis products, which are part of its core Charms business, and a new Talisman collection that highlight lab-grown diamonds. Both will be launched at the end of September. 'I think Minis in particular, but also Talisman, will offer very, very attractive price points for the concept that we're offering,' said Lacik, adding that Pandora will also 'keep bringing new aesthetics and new ideas into the Moments and the Core platforms. So then you have a spill-over effect, that there's something happening overall with the core.' Citi added: 'Despite various external headwinds, including subdued consumer sentiment in developed markets and fixed income, commodities and tariffs, management should not deviate from its long-term goal to become a full jewelry brand. In our view, operating across all categories — well beyond bracelets and charms, which account for only 20 percent of the jewelry market — will require ongoing innovation.' Best of WWD A Brief History of Cartier's 'Love' Fine Jewelry Collection A Look Back at Kate Middleton's Cartier Wedding Day Tiara on Her 13th Wedding Anniversary: A Brief History of the Royal Family's Tradition David Yurman Files Lawsuit Against Mejuri, Alleging 'Serial' Copying Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Elutia Inc (ELUT) Q2 2025 Earnings Call Highlights: Strong EluPro Growth Amid Financial Challenges
BioEnvelope Revenue: Up 33% year over year, reaching a $14 million run rate. EluPro Growth: 49% sequential growth for the quarter, now comprising 68% of BioEnvelope revenue. Hospital Systems: 161 hospital systems actively ordering EluPro. Sales Performance: EluPro sales per account are 130% higher than CanGaroo. Distributor Network: 1,099 distributors, contributing 33% of total sales. Boston Scientific Partnership: Involved in 98 hospitals, facilitating 30% of EluPro cases. Total Quarterly Sales: $6.3 million for the quarter. Gross Margin: Adjusted gross margin at 62.4% for Q2, up over 4 percentage points from a year ago. Adjusted EBITDA: $3.8 million loss for the quarter. Cash Position: Ended Q2 with $8.5 million in cash. Warning! GuruFocus has detected 5 Warning Signs with ELUT. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Elutia Inc (NASDAQ:ELUT) reported a 49% sequential growth in EluPro sales, driven by securing seven national GPO contracts and expanding into 161 hospital systems. The company has developed a strong partnership with Boston Scientific, which is actively involved in EluPro sales in 98 hospitals, facilitating 30% of EluPro cases. Elutia Inc (NASDAQ:ELUT) has achieved significant recognition for its drug-eluting technology, winning multiple awards including the Edison Award and Medical Device Network Excellence Awards. The company is making substantial progress in the breast reconstruction market with its NXT-41x platform, aiming to address significant unmet medical needs. Elutia Inc (NASDAQ:ELUT) has settled 97 out of 110 lawsuits related to a past product recall, reducing legal expenses and removing a significant overhang on the company. Negative Points Elutia Inc (NASDAQ:ELUT) faces challenges in scaling VAC approvals, which are crucial for revenue growth, with a current target of 1,600 hospital centers. The company is still dealing with 13 unresolved lawsuits from a past product recall, which continue to pose a potential financial and reputational risk. SimpliDerm sales have underperformed, generating $2 million in revenue, which is lower than previous quarters. Elutia Inc (NASDAQ:ELUT) reported a $3.8 million adjusted EBITDA loss for the quarter, indicating ongoing financial challenges despite revenue growth. The company has $8.5 million in cash, which may be insufficient for future growth initiatives without successful business development transactions. Q & A Highlights Q: What are the current bottlenecks for EluPro's growth, and how is Elutia addressing them? A: C. Randal Mills, CEO, explained that initially, the commercial team challenged the operations team to keep up with production, but they have since mastered it, as reflected in improved gross margins. The main focus now is scaling VAC approvals, as revenue growth is directly tied to the number of hospitals ordering EluPro. The company is targeting 1,600 centers and maintains a strong pipeline of VAC submissions, with Boston Scientific aiding in opening new accounts. Q: Can you provide more details on the NXT-41 development timeline and its relation to SimpliDerm? A: C. Randal Mills, CEO, stated that the NXT-41 platform will be launched in two phases: the base matrix in the second half of 2026 and the drug-eluting version in the first half of 2027. The base matrix is a new engineered product, not derived from SimpliDerm, designed to eliminate donor variability. SimpliDerm helps establish key accounts and relationships, but NXT-41 aims to offer a more complete solution. Q: How soon can we expect updates on business development activities? A: C. Randal Mills, CEO, mentioned that while nothing is finalized, they expect to conclude at least one transaction in the coming weeks or quarters. He emphasized the importance of not rushing the process to ensure quality outcomes. Q: What are the prospects for maintaining or expanding gross margins, especially with cardiovascular products back in the mix? A: Matthew Ferguson, CFO, highlighted opportunities for gross margin improvement across all segments. EluPro's scaling will enhance margins, cardiovascular products already have high margins over 80%, and there are efficiency improvements possible with SimpliDerm. Q: What level of clinical evidence is needed for FDA approval of NXT-41's base matrix and drug-eluting version? A: C. Randal Mills, CEO, explained that both versions will follow the same regulatory pathway as EluPro, involving the Center for Device and Radiologic Health and the Center for Drugs. The staggered launch allows for clinical data generation to support long-term success, with the base matrix proving its efficacy before adding the drug-eluting component. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
2 days ago
- Bloomberg
True's New CEO Shifting Product Focus for Thai Telecom Leader
True Corp. Pcl plans to shift into higher-margin software services to leverage Thailand's largest mobile subscriber network that currently focuses on basic phone and WiFi connectivity, its new chief executive officer said. The telecom operator became No. 1 by total subscribers through the merger of two of Thailand's three biggest wireless operators – True and Total Access Communication Pcl – a deal finalized in March 2023. But the enlarged company is still 'basically just selling data connectivity,' said Group CEO Sigve Brekke, who took over in March after spending much of the past two decades holding senior roles at Total Access and Norway's Telenor ASA — now True's largest shareholder.
